Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Trastuzumab Deruxtecan Maintains PFS Benefit Across Subgroups in HER2+ Metastatic … – OncLive,

Trastuzumab deruxtecan was evaluated in a single-arm, phase 2 clinical trial in [patients with] heavily pretreated HER2-positive metastatic breast …, Trastuzumab deruxtecan was evaluated in a single-arm, phase 2 clinical trial in [patients with] heavily pretreated HER2-positive metastatic breast …, Read More

Scroll to Top